Forum Report: Issues in Clinical Trials of Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients by Bennett, John E. et al.
Empirical Antifungal Therapy and Neutropenia • CID 2003:36 (Suppl 3) • S117
S U P P L E M E N T A R T I C L E
Forum Report: Issues in Clinical Trials
of Empirical Antifungal Therapy in Treating
Febrile Neutropenic Patients
John E. Bennett,1 John Powers,3 Thomas Walsh,2 Claudio Viscoli,9 Ben de Pauw,8 William Dismukes,4
John Galgiani,5 Michel Glauser,10 Raoul Herbrecht,11 Carol Kauffman,6 Jeannette Lee,4 Peter Pappas,4 John Rex,7
and Paul Verweij8,a
1Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and 2National Cancer
Institute, National Institutes of Health, Bethesda, Maryland; 3Division of Special Pathogen and Immunologic Drug Products, US Food and Drug
Administration, Rockville, Maryland; 4University of Alabama at Birmingham; 5VA Medical Center and University of Arizona, Tucson; 6VA Medical
Center and University of Michigan, Ann Arbor; 7University of Texas Medical School, Houston; 8University Hospital St. Radboud, Nijmegen, The
Netherlands; 9University of Genoa, National Institute for Cancer Research, Genoa, Italy; 10University Hospital, Lausanne, Switzerland; and 11Hoˆpital
de Hautepierre, Strasbourg, France
There is inferential evidence that some patients with prolonged neutropenia and fever not responding to
antibacterial agents are at sufficient risk of deep mycoses to warrant empirical therapy, although superiority
of an antifungal agent over placebo has not been conclusively demonstrated. Amphotericin B deoxycholate,
liposomal amphotericin B, and intravenous itraconazole followed by oral itraconazole solution are licensed
in the United States for this indication. Fluconazole and voriconazole have given favorable results in clinical
trials of patients with low and high risk of deep mold infections, respectively. Design features that can
profoundly influence outcome of empirical trials are (1) inclusion of low-risk patients, (2) failure to blind the
study, (3) obscuration of antifungal effects by changing antibacterial antibiotics, (4) failure to balance both
arms of the study in terms of patients with prior antifungal prophylaxis or with severe comorbidities, (5) the
merging of end points evaluating safety with those of efficacy, and (6) choice of different criteria for resolution
of fever.
BASIS FOR THE CONCEPT OF EMPIRICAL
ANTIFUNGAL THERAPY
The practice of administering empirical antifungal ther-
apy to persistently febrile neutropenic patients who are
apparently not responding to antibacterial therapy has
become a standard of care in many centers. Although
this practice is based on sound theoretical principles,
the actual data from clinical trials supporting the use
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of empirical antifungal therapy in the management of
infections in neutropenic patients are sparse. The initial
suggestions of the possible benefits of an empirical an-
tifungal therapy approach came from autopsy and clin-
ical studies showing an increasing incidence of deep
fungal infections, many recognized only at autopsy, in
patients with cancer [1]. Clinical observations also sug-
gested the importance of early intervention in the suc-
cessful treatment of fungal infections. The difficulty in
making an antemortem diagnosis of invasive fungal
infection, given the limitations of current diagnostic
techniques, necessitates an empirical approach to drug
therapy.
On the basis of these observations, Pizzo et al. [2],
at the National Cancer Institute, performed the first
randomized trial of empirical antifungal therapy in
treating persistently febrile neutropenic patients not re-
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sponding to antibacterial therapy. They studied 50 patients with
fever and neutropenia persisting after 7 days of empirical an-
tibacterial therapy and without documented infection. Patients
were randomized to discontinue all antibiotic treatments (16
patients), to continue the initial antibacterial treatment (16
patients), or to add empirical amphotericin B deoxycholate (18
patients). When results for the 2 groups not receiving ampho-
tericin B deoxycholate were combined, 6 patients developed
fungal infections—4 with deep fungal infections and 2 with
more-superficial disease. Among the 18 patients receiving am-
photericin B deoxycholate, there was only one severe fungal
infection, and it was caused by Pseudallescheria boydii, a species
resistant to amphotericin B. The difference in breakthrough
deep fungal infections did not reach statistical significance in
this small study (6/32 vs. 1/18; ).P 1 .10
Subsequently, Franc¸oise Meunier and the International An-
timicrobial Therapy Cooperative Group of the European Or-
ganization for the Research and Treatment of Cancer (EORTC)
performed another trial of empirical antifungal therapy among
132 persistently febrile and neutropenic cancer patients not
responding to 4 days of treatment with empirical antibacterial
therapy. The investigators randomized patients to receive em-
pirical amphotericin B deoxycholate or to continue antibac-
terial therapy without modification [3]. The primary end point
for this trial was resolution of fever during 5 days of ampho-
tericin B deoxycholate treatment: 69% of patients in the am-
photericin B deoxycholate arm and 53% in the placebo arm
had resolution of fever, a difference that was not statistically
significant. In a subset analysis, there were no deaths due to
fungal infection among patients receiving empirical ampho-
tericin B deoxycholate, compared with 4 deaths in the group
not receiving antifungal therapy ( ). In addition, thePp .05
number of documented fungal infections was higher among
patients not receiving amphotericin B deoxycholate (6 vs. 1;
, Fisher’s exact test). Multivariate analysis with linearPp .056
logistic regression showed that the addition of amphotericin B
deoxycholate correlated with defervescence in adults with he-
matologic malignancies who were not receiving antifungal pro-
phylaxis and who were severely neutropenic ( ). ThesePp .03
results led to the suggestion that empirical antifungal therapy
probably should be reserved for selected groups of high-risk
patients.
At the time these studies were conducted, they were consid-
ered to be at the leading edge of antifungal therapy research
in cancer patients. Now it is apparent that several factors com-
plicate the conclusions of these trials. Neither of the studies
was blinded. Both trials were statistically underpowered to de-
termine differences in both the primary end points and the
subgroup analyses. Although the optimal time at which em-
pirical antifungal therapy should be started remains undeter-
mined, many experts recommend waiting until the fifth or
seventh day of persistent fever and neutropenia before initiating
treatment [4].
DRUGS FOR EMPIRICAL ANTIFUNGAL
THERAPY
A drug for use for empirical antifungal therapy in treating
febrile neutropenic patients should have demonstrable activity
against the fungal pathogens most likely to infect these patients,
namely Candida and Aspergillus species. Amphotericin B deox-
ycholate has been the drug of choice. However, nephrotoxicity
and infusion-related reactions are important limiting factors
with this drug. Concerns with the toxicity of amphotericin B
deoxycholate have led to the study of 3 triazoles and 2 lipid
formulations of amphotericin B for empirical antifungal ther-
apy to treat febrile neutropenic patients.
In 1996, Viscoli et al. [5] reported the first randomized trial
of fluconazole as empirical antifungal therapy. They investi-
gated a selected population of 112 patients who were not re-
ceiving fluconazole prophylaxis and who were at low risk for
invasive aspergillosis. Response to fluconazole was not more
than 10% worse than that to amphotericin B deoxycholate. In
a more recent study of 317 patients, fluconazole was not found
to be inferior to amphotericin B deoxycholate as empirical
antifungal therapy [6].
Investigators also have studied triazoles with greater activity
against Aspergillus species in empirical antifungal therapy trials.
Recent trials with these triazoles have compared itraconazole
with amphotericin B deoxycholate [7] and voriconazole with
liposomal amphotericin B [8]. Two randomized double-blind
trials have compared efficacy of amphotericin B formulations
as empirical therapy for persistent fever in neutropenic patients.
A study by Walsh et al. [9] found liposomal amphotericin B
to be comparable in efficacy but less toxic than amphotericin
B deoxycholate. White et al. [10] found amphotericin B col-
loidal dispersion to have comparable efficacy to but different
toxicity than amphotericin B deoxycholate. Although ampho-
tericin B lipid complex (Abelcet) has been compared with li-
posomal amphotericin B as empirical therapy in a randomized
double-blind trial, the study was designed to compare safety
and not efficacy [11]. As a result of these studies, liposomal
amphotericin B and itraconazole have been approved by the
US Food and Drug Administration for empirical therapy in
treating febrile neutropenic patients.
The recent efficacy trials of empirical therapy have important
similarities and differences. All were randomized, but the itra-
conazole and voriconazole trials were not double-blind [9]. All
used similar composite end points, as discussed below. How-
ever, small differences in the definitions of these end points
resulted in profound differences in the success rates across these
trials.
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PATIENT SELECTION
Selection of high-risk patients. The rationale for empirical
antifungal therapy in treating persistently febrile neutropenic
patients is to treat clinically occult fungal infections and to
prevent subsequent development of mycoses. The key to study
design and clinical practice is to identify patients at high risk
of a mycosis, to use the best diagnostic tests available for iden-
tifying an infectious cause for the fever and, failing diagnosis,
to treat with an antifungal agent. If none of the patients in a
trial actually have an occult mycosis, then the antifungal drugs
being compared will be equivalent because they are equally
unnecessary.
Empirical antifungal therapy is best targeted to the patients
with prolonged neutropenia (usually 110 days’ duration), such
as those with acute leukemia and myeloablative allogeneic he-
matopoietic stem cell transplant recipients. Host factors are an
important factor in assessing risk and may change over time.
For example, some recipients of autologous hematopoietic stem
cell transplants and patients with lymphoma were previously
considered at risk for invasive mycoses. However, as the result
of cytokine therapy and peripheral blood stem cells, the risk is
now diminished. On the basis of the current practices of an-
tineoplastic therapy, most febrile neutropenic patients with
solid tumors or lymphomas and recipients of autologous he-
matopoietic stem cell transplants appear to be at low risk of
an occult deep mycosis because the duration of neutropenia is
usually short. Neutropenia (!500 neutrophils/mm3) in these
patients rarely lasts 18–10 days. Patients who present with fever
on day 3 of neutropenia might be enrolled in an empirical
antifungal therapy study on day 8 or 9, at which point their
neutropenia would soon resolve.
Inclusion of patients who have antibacterial therapy mod-
ified prior to enrollment. Modification of the empirical an-
tibacterial regimen on the basis of persistent fever in neutro-
penic patients is common in hematology/oncology centers. The
most frequent modification is the addition of a glycopeptide,
such as vancomycin. If the patient is enrolled in a clinical trial
of empirical antifungal therapy 24–48 h after alteration of the
antibacterial regimen, it is difficult (in absence of microbio-
logical data) to assess the relative merits of either the new
antibacterial agent or the antifungal drug. More discussion is
necessary on how to analyze the efficacy of antifungal therapy
for a patient whose antibacterial regimen is altered after ran-
domization to empirical antifungal therapy.
Inclusion of patients with microbiologically documented in-
fections. Patients with clinically documented bacterial, fun-
gal, viral, or protozoan infections were excluded from the
EORTC study, the fluconazole trial [5], and the itraconazole
trial [7]. The trials of liposomal amphotericin B and voricon-
azole included an unspecified number of patients with “con-
trolled” bacteremia; however, no definition of “controlled” bac-
teremia was provided in the reports. Patients with bacteremia
may take 13–4 days to defervesce. If these patients are included
in trials of empirical antifungal therapy, resolution of fever may
be erroneously ascribed to treatment of an occult fungal in-
fection and therefore may dilute the treatment effect of anti-
fungal therapy.
NEED FOR BLINDING THE STUDIES
The more subjective the end point, the more there is a need
for blinding the patient, the investigator, and the sponsor to
the study drug. In clinical trials of new antifungal agents, there
may be a potential bias against the efficacy of a new drug. Lack
of confidence in a new drug may increase discontinuations
because of perceived lack of efficacy in a nonblinded study.
Similarly, anticipation of amphotericin B toxicity may intro-
duce a bias in unblinded physicians toward early discontinu-
ation of that drug. Documentation in the case report form to
validate the reason for early discontinuation has often been
scanty and would benefit from an explanation in text form,
particularly in unblinded trials.
Problems with blinding may arise in comparing a drug avail-
able only as an intravenous formulation with a drug with both
intravenous and oral formulations. In this situation, it is logical
that both the sponsor and the investigator are interested in
exploring the possibility of sequential intravenous to oral ther-
apy. Blinding the study may make such sequential therapy more
difficult. For example, in the studies evaluating voriconazole
and itraconazole for empirical antifungal therapy, blinding the
studies might have precluded an understanding of the benefits
of oral therapy following initial intravenous azole treatment.
However, blinding would have reduced potential investigator
bias in early discontinuations of patients from the study. The
studies of itraconazole and voriconazole for empirical therapy
clearly demonstrated this problem [7, 8]. There were more early
discontinuations due to persistence of fever, perceived as in-
efficacy, among patients receiving the experimental drug than
among those receiving the comparator drug. In these non-
blinded trials, the question remains as to the degree to which
these discontinuations were influenced by potential investigator
bias.
THE CONCEPT OF THE COMPOSITE END POINT
The EORTC empirical antifungal therapy trial used resolution
of fever as the main end point of efficacy. Because fever was
required for entry into the study, resolution of fever was a
logical end point. Given the numerous causes of fever in neu-
tropenic patients, this end point lacks specificity and is no
longer used as the sole efficacy end point in empirical antifungal
therapy trials. There is general agreement that the most clini-
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cally relevant end point in these trials is the absence of break-
through fungal infections. However, patients who discontinue
therapy early because of lack of efficacy, or who die while
undergoing therapy and do not undergo autopsy, would have
to be considered to have occult breakthrough infections, given
the lack of specific diagnostic tests for such infections. With
these considerations in mind, recent trials in empirical anti-
fungal therapy have used a 5-component composite end point,
representing a significant advance in the design of trials of
empirical antifungal therapy in treating persistently febrile neu-
tropenic patients [8, 9]. The components of the composite end
point include successful treatment of any baseline fungal in-
fection, absence of breakthrough fungal infection, resolution
of fever at some designated time point, survival at some des-
ignated time point, and no premature discontinuation of drug
because of lack of efficacy or toxicity.
The main concern with a composite end point is that in-
vestigators have attached importance to analyses of individual
end points, such as the number of breakthrough fungal infec-
tions, even though these studies are not usually powered ad-
equately to determine differences in the individual components
of the composite end point. Even when the individual end
points are planned for analysis before the start of the study,
calculation of statistical probabilities for secondary end points
remains a dubious exercise. This approach is particularly ques-
tionable if the study fails to prove that the drugs are noninferior
to each other on the basis of the overall success rates with the
primary composite end point. Whether the trial succeeds or
fails, secondary end points are best used to generate hypotheses
for future studies, not for analysis of a completed study.
Successful treatment of baseline fungal infections. Pa-
tients with known, documented, invasive fungal infections are
excluded from clinical trials of empirical antifungal therapy.
However, for some patients, investigators become aware after
randomization of the results of cultures and histopathology
done around the time of enrollment. These studies may reveal
that these patients did have a baseline fungal infection. Suc-
cessful therapy for these baseline fungal infections is one mea-
sure of antifungal drug efficacy; however, this component of
the composite end point usually does not have a major effect
on the overall outcome of the trial because the number of
baseline infections is usually small. The majority of these pa-
tients are excluded before enrollment. Nevertheless, measure-
ment of the outcome for these patients by a blinded review
panel provides important insight into the efficacy of the an-
tifungal compound.
It is important to establish protocol-defined, standardized,
diagnostic workups to screen for baseline fungal infections be-
fore study entry. There may be major differences across centers
in the ability to diagnose invasive fungal infections, leading to
possible imbalances between centers. An infection that would
be detected and either excluded from the trial or categorized
as a baseline infection may be detected later in another center
and categorized as a breakthrough fungal infection.
Absence of breakthrough fungal infections. A break-
through mycosis represents unsuccessful treatment of an occult
mycosis or emergence of a new mycosis during empirical an-
tifungal therapy. Incidence of breakthrough fungal infections
is one of the most objective ways of measuring drug efficacy
in empirical trials. However, there are several important con-
siderations in evaluating breakthrough fungal infections.
Establishing common definitions of both baseline and break-
through infections seems crucial. Because there are currently
no accepted distinctions between baseline and breakthrough
fungal infections, it may be difficult to separate fungal infections
into one of these categories. Separation of baseline from break-
through infections is an important distinction. The mere pres-
ence of a baseline fungal infection (rather than the cure of such
an infection) is not a measure of drug efficacy, given that a
baseline infection was present before initiation of antifungal
therapy. On the other hand, the incidence of breakthrough
infections in patients already receiving antifungal therapy may
be an important measurement of difference in efficacy between
2 drugs.
A clinical trial of empirical antifungal therapy that makes
use of prevention of breakthrough infections as the sole end
point may require an impracticably large number of patients
to achieve adequate statistical power. The true incidence of
baseline and breakthrough fungal infections in persistently feb-
rile and neutropenic patients in the absence of empirical an-
tifungal therapy is unknown. In the early EORTC trial, the
incidence of fungal infections among patients randomized to
the group that did not receive empirical antifungal therapy was
9.4% [3]. More recent empirical antifungal therapy trials in
which all patients have received empirical antifungal therapy
have shown incidences of baseline and breakthrough infections
ranging from 2% to 9% [7–9]. A study with adequate statistical
power to show a reduction in breakthrough fungal infections
from 9% to 4% with a new drug compared with some standard
therapy (a superiority trial design) would require a sample size
of 11000 patients. A noninferiority trial designed to show that
a new drug was not worse than the comparator by some defined
amount would need a comparably large number of patients.
The exact number of patients would depend on the noninfer-
iority margin selected for the trial and the success rate of the
drugs used in the trial. Determining the acceptable difference
in breakthrough fungal infections between 2 regimens (the non-
inferiority margin or “delta”) in a noninferiority trial is prob-
lematic without knowing the incidence in patients receiving no
antifungal therapy. If the incidence without empirical antifungal
therapy were 9%, the delta would need to be somewhat lower
than 9% to allow for some margin of benefit over no treatment
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and to allow for some margin of error in the trial. In the worst-
case scenario, the study drug could be judged noninferior to
the control agent whereas one or both of the drugs may have
no benefit over no empirical antifungal therapy.
Resolution of fever as an end point. Resolution of fever
has been a time-honored end point in early empirical antifungal
therapy trials. This end point allows some continuity with pre-
vious trials such as the EORTC study, upon which the concept
of empirical antifungal therapy is based. Patients considered to
have occult fungal infections at the time of enrollment on the
basis of the presence of fever may still harbor these infections
if they remain febrile at the end of therapy. However, fever in
neutropenic cancer patients or allogeneic bone marrow trans-
plant recipients may have numerous causes, such as neoplasm,
drug reaction, or bacterial or viral infection, other than occult
fungal infection. Therefore, fever is a relatively nonspecific
marker for both the presence of an occult fungal infection and
the clinical response to an empirically administered antifungal
drug.
In recent trials of empirical antifungal therapy, the resolu-
tion-of-fever component of the composite end point has ex-
erted a large influence on the overall outcome of the trials. The
timing of the assessment of resolution of fever has not been
consistent across trials, accounting for some of the differences
in the success rates for both the resolution-of-fever end points
and the overall outcomes for these recent trials. For example,
in the study evaluating liposomal amphotericin B [9], resolu-
tion of fever was assessed at the time the absolute neutrophil
count reached 500/mL and was 58% for liposomal amphotericin
B and 58% for amphotericin B deoxycholate. In the study
evaluating itraconazole compared with amphotericin B deox-
ycholate [7], the time point for assessment of resolution of
fever was up to 28 days after start of therapy. The success rates
for the resolution-of-fever component of the composite end
point were 73% for itraconazole and 70% for amphotericin B
deoxycholate. In the study evaluating voriconazole compared
with liposomal amphotericin B, the timing of assessment of
the resolution of fever was 48 h before an increase in the ab-
solute neutrophil count to 1500/mL. This more stringent cri-
terion and the short duration over which the study drugs were
given (median of 7 days) resulted in lower success rates for
resolution of fever than in the previous trials, with 33% for
voriconazole and 36% for liposomal amphotericin B.
Compared with a dichotomous value of assessing resolution
of fever at a certain time point, one could consider evaluating
the time to defervescence by means of a Kaplan-Meier analysis.
Including a nondichotomous end point such as time to reso-
lution of fever may be more difficult when used as part of a
composite end point, and this requires further discussion. Some
experts have suggested that resolution of fever could be con-
sidered a secondary end point.
Survival as an end point. A patient who dies while re-
ceiving empirical antifungal therapy may have died as a result
of an occult fungal infection or a comorbid condition, such as
their underlying malignancy or complications of treatment.
Blinded data review committees can review an investigator’s
assessment of fungal-related deaths, but it is often difficult for
investigators to assess the exact cause of death in these com-
plicated patients, even after an autopsy. Therefore, all deaths
are classified as treatment failures.
In most studies, 185% of patients have survived beyond the
completion of empirical antifungal therapy; therefore, this end
point has not been a major cause of failure in the composite
end point. Timing of the measurement of survival as a part of
the composite end point has not been consistent in empirical
antifungal therapy trials. Some trials have assessed survival
within 7 days of the end of therapy. The itraconazole study
assessed survival between 3 and 28 days after the start of therapy
[7]. When assessment of survival is used as an end point, there
is a potential for bias from disparities in randomization in the
severity of underlying disease, and especially in the rate of
comorbidities between treatment arms. Stratification at time of
randomization on the basis of severity of underlying disease
may help reduce this potential confounder.
Discontinuation for toxicity or lack of efficacy as an end
point. Recent trials of empirical antifungal therapy have clas-
sified patients as having experienced treatment failure if they
discontinued the drug early because of either lack of efficacy
or drug toxicity. This end point combines the measurement of
drug efficacy, the intended end point, with drug safety and
masks important differences between drugs. Although lack of
efficacy may be considered an issue of safety as well, it is often
more informative to evaluate these 2 aspects of a drug sepa-
rately. Drugs with lower efficacy but few discontinuations due
to toxicity may appear noninferior to drugs that are more ef-
fective but are more often discontinued for toxicity. Just such
a situation occurred in the trial comparing itraconazole with
amphotericin B deoxycholate [7].
Using a composite end point: summary. Used correctly,
this 5-component composite end point seems appropriate for
the overall assessment of drug efficacy in clinical trials of em-
pirical antifungal therapy in treating high-risk patients. If break-
through fungal infections and survival were the only end points,
the sample size for such trials might be too large to be practical,
particularly for lower-risk patients.
ANALYSIS OF ANTIFUNGAL PROPHYLAXIS
PRIOR TO EMPIRICAL ANTIFUNGAL THERAPY
Stratification of patients before randomization with respect to
prior antifungal prophylaxis is essential and commonly done.
However, stratification of patients does not examine the effect
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of antifungal prophylaxis on the efficacy of the drugs used as
empirical antifungal therapy. In most of these studies,
40%–50% of patients have received prophylaxis before entering
the trial. The effects of prophylaxis on outcome of empirical
therapy have been difficult to analyze because the prophylactic
drug and duration of prior therapy have been heterogeneous.
If empirical antifungal studies are to focus on high-risk patients,
it is most likely that an even larger percentage of study patients
will be receiving antifungal prophylaxis. Future studies should
include a detailed secondary analysis of the effect of antifungal
prophylaxis on empirical antifungal drug efficacy. It may be
useful to require some uniformity of prophylaxis in the period
immediately prior to study entry. Important questions would
include whether antifungal prophylaxis with a particular tria-
zole affects the efficacy of another triazole or an amphotericin
B product when used as empirical antifungal therapy.
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